NCT00105092View on ClinicalTrials.gov

Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 31, 2005

Study Completion Date

February 28, 2007

Conditions
Non-Small-Cell Lung Carcinoma
Interventions
DRUG

Enzastaurin HCL

Trial Locations (3)

Unknown

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Tampa

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Nashville

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Houston

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT00105092 - Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer. | Biotech Hunter | Biotech Hunter